Summary
Four different plasma-derived concentrates composed of coagulation factor VIII (FVIII) and von Willebrand factor (vWF) of varying quality (Hemate-P, Behring; Profilate, Alpha; and FVIII-VHP-vWF, C.R.T.S Lille), or almost purified vWF (Facteur Willebrand, C.R.T.S Lille) and one recombinant FVIII concentrate (Recombinate, Baxter) were given, in doses of 30–60 IU VIII:C/kg or 70–110 IU RCof/kg, to five patients with von Willebrand's disease type III, in order to evaluate the role of the vWF in factor FVIII concentrates. All plasma concentrates except Profilate had a multimeric vWF pattern almost similar to that of normal plasma. Bleeding time (b.t.), VIII:C, vWF: Ag, ristocetin cofactor activity, and multimeric pattern of the plasma-vWF were followed for 72 h. Both Duke b.t. and the multimeric pattern in plasma normalized after infusion of Hemate-P, FVIII-VHP-vWF, and Facteur Willebrand and, to a lesser extent, after Profilate. As expected, in response to Recombinate there was no effect on primary hemostasis, and the half-life of FVIII procoagulant activity (VIII:C) was very short. Normalization of the vWF is important not only for improving the primary hemostasis, but also for maintaining the plasma FVIII concentration on a high level, both by reducing the elimination rate of infused FVIII and via a secondary release of endogenous FVIII. If a prompt hemostatic effect is required, we recommend a concentrate containing both FVIII and all vWF multimers, but for prophylactic treatment, pure vWF may be used.
Similar content being viewed by others
References
Aledort LM (1991) Von Willebrand's disease — a therapeutic challenge. Biomedical Progress 4: 43–46
Baumgartner HR, Muggli R (1976) Adhesion and aggregation: morphologic demonstration, quantitation in vivo and in vitro, chap. 1. In: Gordon JL (ed) Platelets in biology and pathology. North Holland Amsterdam, pp 23–66
Bennett E, Dormandy K (1966) Pool's cryoprecipitate and exhausted plasma in the treatment of Willebrand's disease and factor XI deficiency. Lancet 2: 731–732
Berntorp E, Nilsson IM (1988) Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol 40: 205–214
Berntorp E, Nilsson IM (1989) Use of a high-purity factor VIII concentrate (Hemate-P) in von Willebrand's disease. Vox Sang 56: 212–217
Björkman S, Carlsson M, Berntorp E, Stenberg P (1992) Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 22: 385–295
Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR (1976) Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA 236: 2770–2772
Burnouf-Radosevich M, Burnouf T (1992) Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang 62: 1–11
Cumming AM, Fildes S, Cumming IR, Wensley RT, Redding OM, Burn AM (1990) Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease. Br J Haematol 75: 234–239
Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci PM (1989) Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol 73: 93–99
Goudemand J, Mazurier C, Marey A, et al. (1992) Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low FVIII activity. Br J Haematol 80: 214–221
Gralnick HR, Rick ME, McKeown LP, et al. (1986) Platelet von Willebrand factor: an important determinant of the bleeding time in type-I von Willebrand's disease. Blood 68: 58–61
Kaufman RJ, Wasley LC, Dorner AJ (1988) Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 263: 6352–6362
Koedam JA, Meijers JCM, Sixma JJ, Bouma BN (1988) Inactivation of human factor VIII by activated protein C: cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 82: 1236–1243
Lamme S, Wallmark A, Holmberg L, Nilsson IM, Sjögren H-O (1985) The use of monoclonal antibodies in measuring factor VIII/von Willebrand factor. Scand J Lab Invest 45: 17–26
Lethagen S, Nilsson IM (1992) DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand Factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 49: 7–13
Lethagen S, Ostergaard H, Nilsson IM (1986) Clinical application of the chromogenic assay of factor VIII in haemophilia A, and different variants of von Willebrand's disease. Scand J Haematol 37: 448–453
Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1: 869–872
Mannucci PM, Lombardi R, Bader R, et al. (1985) Heterogeneity of type-I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 66: 796–802
Mannucci PM, Moia M, Rebulla O, Altieri D, Monteagudo J, Castillo (1987) Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 25: 55–65
Mazurier C, Jorieux S, de Romeuf C, Samor B, Goudemand M (1991) In vitro evaluation of a very-high-purity, solvent/detergent-treated, von Willebrand factor concentrate. Vox Sang 61: 1–7
Nilsson IM (1984) Von Willebrand's disease from 1926–1983. Scand J Haematol 33: 21–43
Nilsson IM, Hedner U (1977) Characteristics of various factor VIII concentrates used in treatment of hemophilia A. Br J Haematol 37: 543–557
Nilsson IM, Lethagen S (1991) Current status of DDAVP formulations and their use. In: Lusher JM, Kessler CM (eds) Hemophilia and von Willebrand's disease in the 1990s. Elsevier Science Publishers, Amsterdam, pp 443–453
Nilsson IM, Blombäck B, Jorpes E, Blombäck M, Johansson SA (1957) Von Willebrand's disease and its correction with human plasma fraction I-O. Acta Med Scand 159: 179–188
Nilsson IM, Blombäck M, Blombäck B (1959) Von Willebrand's disease in Sweden. Its pathogenesis and treatment. Acta Med Scand 164: 263–278
Nilsson IM, Magnusson S, Borchgrevink C (1963) The Duke and Ivy methods for determination of the bleeding time. Thromb Diathes Haemorrh 10: 223–234
Nilsson IM, Kirkwood TBL, Barrowcliffe TW (1979) In vivo recovery of factor VIII: a comparison of one-stage and twostage assay methods. Thromb Haemost 42: 1230–1239
Nilsson IM, Vilhardt H, Holmberg L, Åstedt B (1982) Association between factor VIII-related antigen and plasminogen activator. Acta Med Scand 211: 105–112
Nilsson IM, Borge L, Gunnarsson M, Kristoffersson AC (1984) Factor VIII-related activities in concentrates. Scand J Haematol 33 [Suppl 41]: 157–172
Pasi KJ, Williams MD, Enayat MS, Hili FGH (1990) Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol 75: 228–233
Perkins HA (1967) Correction of the hemostatic defect in von Willebrand's disease. Blood 30: 375–380
Rodhegiero F, Gill JC (1991) Guidelines for the treatment of von Willebrand's disease with plasma derivatives. In: Lusher JM, Kessler CM (eds) Hemophilia and von Willebrand's dis-ease in the 1990s. Elsevier Science Publishers, Amsterdam, pp 497–503
Ruggeri ZM, Zimmerman TS (1981) The complex multimeric composition of factor VIII/von Willebrand factor. Blood 57: 1140–1143
Ruggeri ZM, Mannucci PM, Jeffcoate SL, Ingram GIC (1976) Immunoradiometric assay of factor VIII-related antigen, with observations in 32 patients with von Willebrand's disease. Br J Haematol 33: 221–232
Sakariassen KS, Bolhuis PA, Sixma JJ (1979) Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature 279: 636–638
Schimpf K, Mannucci PM, Kreutz W, et al. (1987) Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with haemophilia and no previous transfusions. N Engl J Med 316: 918–922
Sixma JJ, Sakariassen KS, Beese-Visser NH, Ottenhof-Rovers M, Bolhuis PA (1984) Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 63: 128–139
Tuddenham EGD, Lane RS, Rotblat F, et al. (1982) Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 52: 259–267
Willebrand EA von (1926) Hereditär pseudohemofili. Finska Läkarsällskapets Handlingar 67: 7–12
Zuzel M, Nilsson IM, Åberg M (1978) A method for measuring plasma ristocetin cofactor activity. Thromb Res 12: 745–754
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lethagen, S., Berntorp, E. & Nilsson, I.M. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 65, 253–259 (1992). https://doi.org/10.1007/BF01836069
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01836069